Skip directly to content

Seebri® Breezhaler® (glycopyrronium bromide)

What is Seebri® Breezhaler® (glycopyrronium bromide) and what is it used for?

Seebri Breezhaler is a medicine that contains an active substance called glycopyrronium bromide. This belongs to a group of medicines called bronchodilators. It is available as capsules containing a powder for inhalation.

Seebri Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a long-term lung disease called chronic obstructive pulmonary disease (COPD).

In COPD the muscles around the airways tighten. This makes breathing difficult. This medicine blocks the tightening of these muscles in the lungs and causes the muscles of the airways to relax, making it easier for air to get in and out of the lungs. Seebri Breezhaler is used for maintenance treatment.

Seebri Breezhaler capsules are only used with the Breezhaler inhaler and must not be swallowed. To take a dose, the patient places a capsule into the device, presses the buttons to pierce it and breathes in the powder through the mouth.

The medicine can only be obtained with a prescription.


Reference information
  • The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in London. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See what guidance they offer about Seebri Breezhaler.
  • If you would like to see the Patient Information Leaflet or Summary of Product Characteristics for Seebri Breezhaler these can be found at the electronic Medicines Compendium (eMC).

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse.. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at By reporting side effects, you can help provide more information on the safety of this medicine.

UK/SBR/17-0727(1) | May 2018